The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy

BACKGROUND: Adalimumab is a fully humanized monoclonal antibody inhibitor of tumor necrosis factor-a used to treat various autoimmune disorders. Adalimumab poses a risk for tuberculosis (TB) infection, especially in countries where TB is endemic. OBJECTIVE: Determine the rate of TB infection after a...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Sohaim, Abdullah, Bawazir, Abdullah Saleh, Al-Turki, Turki, Alsafi, Eiman Omar, Al-Roqy, Abdullah, Layqah, Layla, Baharoone, Salim Alawi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497010/
https://www.ncbi.nlm.nih.gov/pubmed/34618606
http://dx.doi.org/10.5144/0256-4947.2021.285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497010/
https://www.ncbi.nlm.nih.gov/pubmed/34618606
http://dx.doi.org/10.5144/0256-4947.2021.285

Ejemplares similares